Background/Objectives: Endometriosis manifests as ectopic endometrial tissue outside the uterine cavity. This lesion can sometimes appear at unusual anatomical sites or within the intestinal tract, growing and mimicking cancer. Such …
Endometriosis may rarely present with atypical manifestations that closely mimic intra-abdominal malignancy or severe pelvic sepsis, resulting in significant diagnostic uncertainty. We present two contrasting cases of presumed severe endometriosis …
What is the incidence of premature ovarian insufficiency (POI) and its associated factors in Ontario, Canada, between 1995 and 2019?
The widespread use of plastic has led to exposure to chemicals like bisphenols (BPs), particularly bisphenol A (BPA), which are crucial in the production of polycarbonate plastics and epoxy resins. …
Background: Endometriosis of the cervix is a rare, non-cancerous disease that can look or behave like cancerous cervical tissue, causing challenges regarding diagnosis and management. Discrimination between benign and malignant …
Background and Clinical Significance: Abdominal wall endometriosis (AWE) is an ectopic endometrial tissue embedded into the anterior abdominal wall, mainly infiltrating the rectus abdominis or oblique muscles and subcutaneous tissue. …
A growing body of literature has revealed that patients with endometriosis are at an increased risk for epithelial ovarian cancer (EOC) and cardiovascular disease (CVD). Endometriosis is a heterogeneous disease …
Endometriosis rarely affects the abdominal wall and typically occurs following surgery, like uterine procedures or, more commonly, cesarean sections. There have been a few instances of endometriosis evolving into malignant …
Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet sex-specific risk factors are usually not included in conventional predictive models. Specifically, heart failure (HF) in women may …
It is critical that women undertaking medically assisted reproductive (MAR) treatment and their clinicians know whether the treatments are associated with an increased risk of hormone-related cancers.